Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
841 to 860 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Tumor Microenvironment in Thymic Epithelial Tumors: A Narrative Review. | Cancers (Basel) | 2022 | 36551568 | PubTator, text mining | PubMed |
| Delivery of Melittin as a Lytic Agent via Graphene Nanoparticles as Carriers to Breast Cancer Cells. | J Funct Biomater | 2022 | 36547538 | PubTator, text mining | PubMed |
| Comprehensive analysis of cuproptosis-related lncRNAs in the prognosis and therapy response of patients with bladder cancer. | Ann Transl Med | 2022 | 36544685 | PubTator, text mining | PubMed |
| Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis. | Cell Rep Med | 2022 | 36543113 | PubTator, text mining | PubMed |
| Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals. | Front Immunol | 2022 | 36532041 | PubTator, text mining | PubMed |
| Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy. | Front Immunol | 2022 | 36532019 | PubTator, text mining | PubMed |
| Cell Differentiation Trajectory Predicts Prognosis and Immunotherapeutic Response in Clear Cell Renal Cell Carcinoma. | Genet Res (Camb) | 2022 | 36530957 | PubTator, text mining | PubMed |
| Intranasal inoculation of IFN-λ resolves SARS-CoV-2 lung infection via the rapid reduction of viral burden and improvement of tissue damage. | Front Immunol | 2022 | 36524125 | PubTator, text mining | PubMed |
| A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors. | PeerJ | 2022 | 36518297 | PubTator, text mining | PubMed |
| Comprehensive analysis of the expression, prognostic significance, and regulation pathway of G2E3 in breast cancer. | World J Surg Oncol | 2022 | 36517818 | PubTator, text mining | PubMed |
| Pediatric-type follicular lymphoma: a short review. | Int J Hematol Oncol | 2022 | 36514787 | PubTator, text mining | PubMed |
| The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma. | Front Oncol | 2022 | 36505882 | PubTator, text mining | PubMed |
| Oncolytic virus: A catalyst for the treatment of gastric cancer. | Front Oncol | 2022 | 36505792 | PubTator, text mining | PubMed |
| Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. | Front Immunol | 2022 | 36505457 | PubTator, text mining | PubMed |
| Integrated bioinformatic analysis identified a novel prognostic pan-programmed cell death signature for bladder cancer. | Front Immunol | 2022 | 36505448 | PubTator, text mining | PubMed |
| Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. | Molecules | 2022 | 36500358 | PubTator, text mining | PubMed |
Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification. | Cancers (Basel) | 2022 | 36497332 | PubTator, text mining | PubMed |
| Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. | Cancers (Basel) | 2022 | 36497266 | PubTator, text mining | PubMed |
| Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis. | Sci Rep | 2022 | 36494415 | PubTator, text mining | PubMed |
| Comprehensive analysis of the relationship between cuproptosis-related genes and esophageal cancer prognosis. | World J Clin Cases | 2022 | 36483804 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=43